Capricor Therapeutics, for instance, is developing cell and exosome-based technologies to treat or prevent a broad range of diseases.

Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of action.

In this episode of Breakthrough Economy, MindMed CEO Robert Barrow chats with Host Jen Rogers about how his company, which was the first psychedelic pharmaceutical company to go public, is working to unlock the full therapeutic potential of psychedelics and other novel therapeutic targets.

Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.

Dr. Mark Sumeray from Amolyt Pharma talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

The vice president of Innovation and New Technologies at Grifols provided perspective on the interim phase 2 findings of ABvac40, a vaccine in development for patients with Alzheimer disease.

Vittoria’s innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of cell therapies.

This week, the Business of Biotech sits down with the legendary biotech investor Steve Gorlin, now CEO of CoRegen, for a conversation on his golden rules for picking winners.